ArticleJournal of advanced research2026
Tripterygium wilfordii multi-glycoside alleviates ankylosing spondylitis via gut microbiota modulation and metabolite reprogramming.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnkylosing spondylitis (AS) is a chronic autoimmune inflammatory disorder characterized by severe inflammation in the axial skeleton. Tripterygium wilfordii multi-glycoside (GTW) is widely used in clinical practice for AS and related immune diseases, yet its precise mechanism of action remains unclear.
objectivesExplore the therapeutic effects of GTW on AS and its potential mechanisms, with a focus on its impact on the gut microbiota and associated metabolites.
methodsAn AS mouse model was established via intraperitoneal injection of proteoglycan and Freund's complete adjuvant. The therapeutic effects and underlying mechanisms of GTW were explored through phenotypic analysis, 16S rRNA sequencing, and metabolomic profiling.
resultsGTW significantly reduced arthritis index, gait score, paw thickness, and pro-inflammatory cytokines in AS mice. Additionally, it modulated mRNA and protein expression related to osteoclast and osteoblast differentiation while restoring intestinal barrier integrity. Notably, GTW reversed the AS-induced depletion of Bifidobacterium and Akkermansia. Correlation analysis between gut microbiota, fecal metabolites, and AS-related phenotypes suggested that GTW-enriched bacteria were positively associated with beneficial metabolites, including 3-methylxanthine, 5'-methylthioadenosine, cinnamic acid, kaempferol, and palmitoyl glucuronide. Both of those gut bacteria and metabolites were strongly negatively correlated with AS severity markers (IL-6, IL-17, IL-23, Th17 cell percentage, arthritis index, gait score, paw thickness, and Rankl expression) and positively associated with protective factors (Zo-1, Occludin, Claudin-1, Ocn, and Alp gene expression).
conclusionsThis study implies that GTW treatment is associated with amelioration of AS-related symptoms in mice, suggesting a potential role of the gut microbiota-metabolite axis in GTW-associated AS improvement, though causal relationships require further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.